Correction: Prophylactic antibiotics to prevent pneumonia and other complications after measles: Community based randomised double blind placebo controlled trial in Guinea-Bissau (BMJ (Online) (2006) 333 (1245) DOI: 10.1136/bmj.38989.684178.AE);Prophylactic antibiotics to prevent pneumonia and other complications after measles: Community based randomised double blind placebo controlled trial in Guinea-Bissau

British Medical Journal

Volumn 333, Issue 7581, 2006, Pages 1245-1247

  Garly, May Lill ^a,c   Balé, Carlitos ^a   Martins, Cesário Lourenco ^a   Whittle, Hilton C ^b   Nielsen, Jens ^a   Lisse, Ida M ^a   Aaby, Peter ^a  

^a Projecto de Saude de Bandim   (Guinea-Bissau)

^b MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; MEASLES VACCINE; PLACEBO;

ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHILD; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEVER; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MEASLES; OTITIS MEDIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THRUSH; TREATMENT FAILURE; VACCINATION; WEIGHT CHANGE;

EID: 33845942030     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i3040     Document Type: Erratum

References (11)

1. Loening WE, Coovadia HM. Age-specific occurrence rates of measles in urban, peri-urban, and rural environments: implications for time of vaccination. Lancet 1983;ii:324-6.
2. Van Den HS, Smit C, Van Steenbergen JE, De Melker HE. Hospitalizations during a measles epidemic in the Netherlands, 1999 to 2000. Pediatr Infect Dis J 2002;21:1146-50.
3. Shann F, D'Souza RM, D'Souza R. Antibiotics for preventing pneumonia in children with measles. Cochrane Database Syst Rev 2006; (3): CD001477.
4. Samb B, Simondon F, Aaby P, Whittle HC, Seck AMC. Prophylactic use of antibiotics and reduced case fatality in measles infection. Pediatr Infect Dis J 1995;14:695-6.
5. World Health Organization. Clinical research an treatment of measles: report of a meeting. Geneva: WHO, 1995. (WHO/CDR/95.15.)
6. Aaby P. Bandim. An unplanned longitudinal study. In: Das Gupta M, Aaby P, Pison G, Garenne M, eds. Prospective community studies in developing countries. Oxford: Clarendon Press, 1997:276-96.
7. Garly M-L, Martins CL, Balé C, da Costa F, Dias F, Whittle HC, et al. Early two-dose measles vaccination schedule in Guinea-Bissau: good protection and coverage in infancy. Int J Epidemiol 1999;28:347-52.
8. Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis 2004;189(suppl 1):4-16.
9. Qazi SA. Antibiotic strategies for developing countries: experience with acute respiratory tract infections in Pakistan. Clin Infect Dis 1999;28:214-8.
10. Klugman KP. The clinical relevance of in-vitro resistance to penicillin, ampicillin, amoxycillin and alternative agents, for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. J Antimicrob Chemother 1996;38(suppl A):133-40.
11. Shann F. Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence. BMJ 1997;314:334-7.